Bone morphogenetic protein-2 (BMP-2)-containing bone grafts are useful regenerative materials for oral and
maxillofacial surgery; however, several in vitro and in vivo studies previously reported
cancer progression-related adverse effects caused by BMP-2. In this study, by quantifying the rhBMP-2 content released from bone grafts, the rhBMP-2 concentration that did not show cytotoxicity in each cell line was determined and applied to the in vitro monoculture or coculture model in the invasion assay. Our results showed that 1 ng/ml rhBMP-2, while not affecting
cancer cell viability, significantly increased the invasion ability of the
cancer cells cocultured with fibroblasts. Cocultured medium with rhBMP-2 also contained increased levels of
matrix metalloproteinases. rhBMP-2-treated cocultured fibroblasts did not show a prominent difference in
mRNA expression profile. Some
cytokines, however, were detected in the
conditioned medium by a human
cytokine antibody array. Among them, the
cancer invasion-related factor CCL5 was quantified by ELISA. Interestingly, CCL5
neutralizing antibodies significantly reduced the invasion of
oral cancer cells. In conclusion, our results suggest that 1 ng/ml rhBMP-2 may induce invasion of
oral squamous cell carcinoma (OSCC) cells by CCL5 release in coculture models. Therefore, we propose that a careful clinical examination before the use of rhBMP-2-containing
biomaterials is indispensable for using rhBMP-2 treatment to prevent
cancer progression.